| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Biologics Contract Manufacturing Market Size 2023 |
USD 21,185.00 million |
| Biologics Contract Manufacturing Market , CAGR |
9.32%. |
| Biologics Contract Manufacturing Market Size 2032 |
USD 51,804.00 million |
Market Overview:
The biologics contract manufacturing market is on a trajectory of substantial growth, with projections indicating a noteworthy increase from USD 21,185.00 million in 2023 to USD 51,804.00 million by 2032, representing a robust compound annual growth rate (CAGR) of 9.32%. The biologics contract manufacturing (Bio-CMO) market is experiencing a substantial growth trajectory, primarily driven by the escalating demand for biologics. The increasing prevalence of chronic diseases and the trend toward personalized medicine are key contributors to the rising demand for biopharmaceuticals. The intricate nature of biologics manufacturing necessitates specialized expertise and infrastructure, leading pharmaceutical and biotechnology companies to turn to bio-CMOs. Partnering with these specialized manufacturers allows companies to optimize costs, enhance efficiency, and focus on core competencies such as drug discovery and development. The evolving regulatory landscape further accentuates the role of bio-CMOs with established compliance procedures and regulatory expertise, providing crucial support to navigate complex regulatory requirements.
One notable trend in the bio-CMO market is the rise of biosimilar development. With patents expiring on several high-value biologic drugs, there is a growing opportunity for the development of biosimilars, and bio-CMOs are well-positioned to contribute their manufacturing expertise. Additionally, the adoption of advanced technologies, including continuous manufacturing and single-use bioreactors, is enhancing efficiency and real-time monitoring in biologics production. Bio-CMOs are also increasingly focusing on specialization, catering to specific areas of biologics manufacturing such as monoclonal antibodies, gene therapies, or viral vectors. This specialization enables them to provide a higher level of expertise tailored to the unique needs of different therapeutic categories.
Amidst these trends, bio-CMOs are capitalizing on opportunities for geographic expansion, tapping into emerging markets where the demand for biologics is growing. This expansion allows them to reach new customer bases and leverage cost advantages in specific regions. Overall, the bio-CMO market presents significant opportunities for investment in expanding manufacturing capabilities, forging strategic partnerships, and focusing on emerging markets to meet the surging demand for biologics.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
This growth is propelled by several key factors shaping the future of biologic contract manufacturing. One primary driver is the escalating global demand for biologics, driven by the increasing prevalence of chronic diseases, advancements in biopharmaceutical research, and a growing focus on personalized medicine. Biologics offer targeted therapies for conditions like cancer and autoimmune disorders, and contract manufacturing provides the necessary flexibility to accommodate the demand for smaller-batch, customized production.
Pharmaceutical and biotechnology companies are increasingly turning to contract manufacturing organizations (CMOs) due to the cost-effectiveness and expertise they provide. As of recent data, there are over 305 biologics CMOs offering contract manufacturing services for biologics. Outsourcing manufacturing to CMOs reduces capital expenditure, allowing companies to access specialized capabilities without significant upfront investment.
This shift also enables companies to focus on their core competencies, such as drug discovery and development, while benefiting from the scalability and flexibility offered by CMOs. The expertise and regulatory compliance of established CMOs further mitigate the risks associated with in-house production, especially for complex biologics.\.
Technological advancements play a pivotal role in the evolution of the biologics contract manufacturing market. Continuous processing, single-use bioreactors, and other innovative technologies contribute to improved efficiency, enhanced product quality, and faster time-to-market for biologics. For instance, Lonza has developed the new innovative platform technology, New GSv9 TM media and feeds maximize yield and batch-to-batch consistency to support recombinant protein production scale-up.
The market is experiencing geographical expansion, with emerging economies like China and India becoming significant players. Government initiatives, cost-competitive advantages, and a growing domestic demand for biologics are driving this expansion. There are 39 contract manufacturing companies operating 47 facilities that can produce protein and peptide-type biologics.
Strategic partnerships between pharmaceutical companies and CMOs are becoming increasingly crucial to navigate the complex and evolving regulatory landscape, ensure compliance with global regulations, and facilitate efficient product approvals. For example, the pharmaceutical company Pfizer announced a partnership with the CMO Wuxi AppTec to develop and manufacture a new biologic drug for cancer.
Market Trends:
- Rising Demand for Biologics: The pharmaceutical and biotechnology sectors are increasingly reliant on biologics, which offer targeted treatment options with fewer side effects compared to traditional drugs. This surge in demand for complex molecules like monoclonal antibodies, vaccines, and cell and gene therapies is creating a robust market for contract manufacturing services.
- Focus on Speed and Efficiency: Bringing new biologics to market quickly is crucial for pharmaceutical companies. Contract manufacturing organizations (CMOs) are responding to this need by investing in advanced technologies and streamlined processes. This allows them to offer faster development timelines and efficient production capabilities, which is particularly important for novel therapeutics.
- Growing Popularity of Biosimilars: The expiration of patents on several high-cost biologic drugs is paving the way for biosimilars, which are highly similar versions of these drugs. CMOs are strategically positioning themselves to capitalize on this opportunity by expanding their biosimilar manufacturing expertise. This trend is expected to further propel the market forward.
- Shifting Geographic Landscape: Previously, the biologics contract manufacturing market was dominated by North America and Europe. However, the landscape is shifting due to rising production costs in these regions. This is leading to an increase in outsourcing to Asia-Pacific countries like China and India, which offer cost-effective manufacturing capabilities and a growing pool of skilled labor.
- Integration of Advanced Technologies: CMOs are continuously adopting advanced technologies like single-use bioreactors, continuous manufacturing processes, and artificial intelligence (AI) to optimize production processes and ensure product quality. This trend towards automation and data-driven decision-making is expected to further enhance efficiency and cost-effectiveness in biologics manufacturing.
Market Restraints and Challenges:
- High Complexity and Regulatory Stringency: Biologics, unlike traditional small-molecule drugs, are complex and often derived from living organisms. This complexity translates to a lengthy and rigorous development process with stringent regulatory requirements. CMOs must possess extensive expertise in handling sensitive biologics, maintaining strict quality control measures, and complying with evolving regulatory guidelines across different geographic regions. This high barrier to entry can limit the pool of qualified CMOs, potentially leading to capacity constraints and impacting timelines for drug development.
- Integration Challenges and Intellectual Property Concerns: Successful biologics contract manufacturing hinges on seamless integration between the drug developer and the CMO. This requires effective communication, technology transfer, and robust project management to ensure smooth production processes and product quality. Additionally, intellectual property (IP) rights can be a point of contention. Clear agreements need to be established to protect the confidential information and proprietary technologies of both the developer and the CMO.
- Cost Pressures and Fluctuating Supply Chains: Cost-effectiveness is a major concern for drug developers, especially in a competitive market. However, the complex nature of biologics manufacturing, coupled with the high investment required for facilities and equipment, can lead to high production costs for CMOs. Furthermore, disruptions in the global supply chain, such as shortages of raw materials or equipment, can further strain costs and lead to production delays. CMOs need to implement robust supply chain management strategies to mitigate these risks.
- Skill Shortage and Evolving Technologies: The biologics manufacturing landscape is constantly evolving, with new technologies and processes emerging. This rapid advancement necessitates a skilled workforce capable of adapting and operating these sophisticated systems. However, there’s a growing concern about the lack of qualified personnel in the biopharmaceutical industry, particularly for specialized tasks like cell line development and protein purification. CMOs need to invest in training programs and talent acquisition strategies to bridge this skill gap.
- Competition and Consolidation: The biologics CMO market is witnessing a rise in competition, with established players expanding their capabilities and new entrants emerging. This can lead to price pressure and a struggle to differentiate services. Additionally, there’s a trend towards consolidation, where larger CMOs acquire smaller players to enhance their capacity and geographic reach. This consolidation can potentially limit choice and potentially impact pricing for drug developers.
Key player:
- Lonza Group
- Samsung Biologics Co., Ltd.
- Patheon by Thermo Fisher Scientific, Inc.
- Cambrex Corporation
- Siegfried Holding AG
- Fujifilm Holding Corporation
- AbbVie, Inc.
- Boehringer Ingelheim
- Recipharm Pharmaceuticals.
- WuXi Biologics
- Catalent, Inc.
Recent Developments:
- In June 2023, the Cell and Gene Therapy Catapult entered into a technology licensing agreement with Albumedix. This collaboration aims to utilize Albumedix’s cutting-edge technology to enhance the manufacturing process of viral vectors, a critical component in gene therapy.
- Also in June 2023, Wuxi Biologics, known for its comprehensive end-to-end solutions for biologics discovery, development, and manufacturing, announced its plans to expand the production capacities for both drug substances and drug products at its Wuppertal, Germany, facility. This expansion is set to bolster its manufacturing capabilities significantly.
- March 2023 saw Samsung Biologics announcing the construction of a fifth manufacturing plant within its Incheon, South Korea facility. This strategic move is in response to the growing market demand, with the new plant expected to have a capacity of 180,000 liters, increasing the total site capacity to 784,000 liters through an investment of KRW 1.9 trillion.
- In February 2023, LOTTE BIOLOGICS revealed its ambitious plan to add three biomanufacturing plants in South Korea, aiming for a total production capacity of 360,000 liters of antibody drugs. These additions are anticipated to significantly contribute to the growth of the biologics contract manufacturing market.
- January 2023 witnessed WuXi Biologics entering into a licensing agreement with GSK plc. This agreement grants GSK an exclusive global license to use WuXi Biologics’ proprietary technology platforms for the research, development, manufacturing, and commercialization of bispecific antibodies.
- In October 2022, Samsung Biologics and GSK plc formed a partnership for the manufacturing of GSK’s monoclonal antibody products, including treatments for lupus like Benlysta.
- On April 20, 2022, Fujifilm Corporation completed the acquisition of a cell therapy manufacturing facility from Atara Biotherapeutics Inc., located in Thousand Oaks, California. This facility will be incorporated into FUJIFILM Diosynth Biotechnologies’ global network, enhancing its position as a leading contract development and manufacturing organization (CDMO).
- In March 2022, Oasmia Pharmaceutical AB and Lonza signed a large-scale manufacturing agreement. This partnership focuses on producing the main drug intermediate for Cantrixil, supplying clinical material for the investigational drug candidate.
Segmentation Analysis:
The segmentation analysis of the biologic manufacturing market highlights the diversity and potential within this sector. Monoclonal antibodies (mAbs) currently dominate the market, primarily due to their widespread application in the treatment of cancers, chronic illnesses, and autoimmune diseases. Vaccines are also experiencing significant growth, driven by an increased emphasis on preventive healthcare and the urgent need for novel vaccines. Gene therapies represent a rapidly advancing segment, offering groundbreaking prospects for addressing genetic disorders. Similarly, cell therapies are emerging as a vital area with substantial therapeutic benefits for a range of conditions. Additionally, the “Other biologics” category, encompassing recombinant proteins, blood factors, and more, is poised for expansion as new biologics are developed and brought to market. Collectively, these segments underscore the dynamic nature of biologic manufacturing and its critical role in advancing medical treatments.
Segmentations:
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- East Asia
- South Asia
- Europe
- Oceania
- MEA
Regional Analysis:
North America, currently commanding the largest market share at approximately 35% in 2023, maintains its dominant position in the biologics contract manufacturing market. This is attributed to the strong presence of well-established pharmaceutical and biotechnology companies, significant investments in research and development (R&D) for biologics, and a well-developed infrastructure with a robust regulatory framework. However, the region faces challenges such as increasing competition from other global regions and escalating manufacturing costs.
Asia Pacific emerges as the region with the fastest growth rate, projecting a compound annual growth rate (CAGR) exceeding 11%. This growth is fueled by rapidly growing economies, increasing disposable income, expanding domestic pharmaceutical markets, and supportive government initiatives fostering the biopharmaceutical industry. Notably, China plays a major role in this regional growth, attracting contract manufacturing activities due to its cost-effectiveness. Nevertheless, potential hurdles include concerns related to intellectual property and navigating evolving regulatory landscapes.
Europe, considered a mature market, maintains a strong focus on innovation and upholds high-quality manufacturing standards. Key drivers in this region include the established presence of major contract manufacturing organizations (CMOs) and stringent regulatory requirements ensuring product quality and safety. Despite these advantages, Europe encounters challenges such as competition from emerging markets and bureaucratic hurdles that may impede its growth in the biologics contract manufacturing sector.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Future Outlook:
- Rising Demand for Complex Biologics: The increasing development of complex biologics, including monoclonal antibodies and gene therapies, will fuel the demand for specialized contract manufacturing organizations (CMOs) with expertise in handling these intricate molecules.
- Growing Adoption of Biologics: The expanding use of biologics across various therapeutic areas, such as oncology, immunology, and neurology, will necessitate increased manufacturing capacity, propelling the CMO market.
- Cost Optimization Strategies: Pharmaceutical and biotechnology companies are increasingly seeking cost-effective solutions for biologics manufacturing. CMOs offering efficient processes and economies of scale will be well-positioned to capitalize on this trend.
- Technological Advancements: Continued advancements in bioprocessing technologies, such as continuous manufacturing and single-use platforms, will enhance efficiency, flexibility, and cost-effectiveness in biologics production, creating further opportunities for CMOs.
- Focus on Geographic Expansion: Biologics CMOs are anticipated to expand their geographic footprint to cater to the growing demand in emerging markets like Asia Pacific and Latin America.
- Strategic Partnerships and Acquisitions: The market is likely to witness an increase in strategic partnerships and acquisitions between pharmaceutical companies and CMOs to bolster expertise and capabilities.
- Regulatory Considerations: Stringent regulatory requirements for biologics manufacturing will necessitate robust compliance strategies from CMOs to ensure product quality and safety.
- Emphasis on Quality and Speed: CMOs that prioritize stringent quality control procedures while ensuring timely delivery of biologics will be attractive partners for pharmaceutical and biotech companies.
- Sustainability Concerns: Growing environmental concerns will likely lead to a rise in demand for sustainable manufacturing practices among CMOs. This could involve adopting eco-friendly technologies and processes.
- Evolving Regulatory Landscape: CMOs that keep pace with the evolving regulatory landscape for biologics manufacturing will be better equipped to navigate future challenges and capitalize on emerging opportunities.
